Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 9/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691661 | 0.86 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL7222018 | 0.85 | GABRA1 (0.59) | KDM4ENPC1RAB9APOLBHTT | |
| Hydrochloric Acid SCHEMBL1430093 | 0.81 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL1431043 | 0.81 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL13341899 | 0.80 | NPC1 (0.55) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL8208 | 0.80 | KDM4E (0.64) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL7223975 | 0.79 | KDM4E (0.65) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL7228643 | 0.78 | KDM4E (0.64) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL7231135 | 0.78 | KDM4E (0.58) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL1430221 | 0.77 | KDM4E (0.67) | KDM4ENPC1RAB9APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | claimed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | claimed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | claimed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | claimed |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
| US-6514969-B2 | Alzheimer's diseas, Parkinson disease, Huntington disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | KDM4E 2671/4885NPC1 1153/4885RAB9A 3798/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | KDM4E 2671/4885NPC1 1153/4885RAB9A 3798/4885 |
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | HTT, APP, BACE1 | KDM4E 4232/4885NPC1 44/4885RAB9A 2085/4885 |
| US-20140206662-A1 | Imidazopyridine Compounds | SSB, NFKBIA, TPMT | KDM4E 2821/4885NPC1 2286/4885RAB9A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.